Chung H Kok

List of Publications by Year
in descending order

57 papers	1,325 citations	471061 17 h-index	360668 35 g-index
57 all docs	57 docs citations	57 times ranked	2987 citing authors

#	Article	IF	Citations
1	Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature Genetics, 2011, 43, 1012-1017.	9.4	524
2	Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2168-2173.	3.3	74
3	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 2018, 32, 2572-2579.	3.3	66
4	Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 2009, 114, 4859-4870.	0.6	52
5	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 2017, 102, e490-e493.	1.7	52
6	Successful treatmentâ€free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, 2020, 191, 433-441.	1.2	52
7	HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget, 2013, 4, 1933-1947.	0.8	48
8	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 2020, 34, 1052-1061.	3.3	39
9	Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. Journal of Leukocyte Biology, 2006, 80, 433-447.	1.5	37
10	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 106.	6.9	29
11	The granulocyte-associated transcription factor KrÃ¼ppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. Leukemia Research, 2012, 36, 110-116.	0.4	28
12	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer, 2018, 118, 1000-1004.	2.9	28
13	Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances, 2019, 3, 1610-1621.	2.5	27
14	Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 2021, 5, 5107-5111.	2.5	25
15	The GM-CSF receptor utilizes Î²-catenin and Tcf4 to specify macrophage lineage differentiation. Differentiation, 2012, 83, 47-59.	1.0	23
16	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 2017, 408, 92-101.	3.2	23
17	Methylation of <scp>KLF</scp>5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. British Journal of Haematology, 2013, 161, 884-888.	1.2	18
18	Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. Blood, 2011, 118, 1675-1675.	0.6	18

#	Article	IF	Citations
19	COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Blood, 2020, 136, 46-47.	0.6	17
20	Interleukin-3-mediated regulation of Î²-catenin in myeloid transformation and acute myeloid leukemia. Journal of Leukocyte Biology, 2014, 96, 83-91.	1.5	13
21	Increased peroxisome proliferator-activated receptor Î³ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica, 2017, 102, 843-853.	1.7	12
22	Modelling ponatinib resistance in tyrosine kinase inhibitor-naÃ¯ve and dasatinib resistant BCR-ABL1+ cell lines. Oncotarget, 2018, 9, 34735-34747.	0.8	12
23	The preferential occurrence of <scp>FLT</scp>3â€<scp>TKD</scp> mutations in inv(16) <scp>AML</scp> and impact on survival outcome: a combined analysis of 1053 coreâ€binding factor <scp>AML</scp> patients. British Journal of Haematology, 2013, 160, 557-559.	1.2	11
24	Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 814.	1.1	11
25	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics, 2017, 216-217, 86-90.	0.2	10
26	GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2010, 116, LBA-3-LBA-3.	0.6	10
27	A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. Journal of Molecular Diagnostics, 2017, 19, 711-721.	1.2	7
28	Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 655201.	1.8	7
29	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	2.0	7
30	Genome-wide gene expression profiling identifies overlap with malignant adrenocortical tumours and novel mechanisms of inefficient steroidogenesis in familial ACTH-independent macronodular adrenal hyperplasia. Endocrine-Related Cancer, 2012, 19, L19-L23.	1.6	6
31	miR-155 as a potential target of IL-3 signaling in primary AML cells. Leukemia Research, 2017, 57, 57-59.	0.4	6
32	p53-Dependent Transcriptional Responses to Interleukin-3 Signaling. PLoS ONE, 2012, 7, e31428.	1.1	6
33	COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. Blood, 2021, 138, 634-634.	0.6	5
34	The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML). Blood, 2020, 136, 25-27.	0.6	4
35	A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. Blood, 2019, 134, 663-663.	0.6	3
36	CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with preâ€Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 171-175.	1.2	2

#	Article	IF	Citations
37	RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2022, 24, 803-822.	1.2	2
38	Highly sensitive droplet digital polymerase chain reaction for <scp>BCR</scp> :: <scp> ABL1 messenger RNA </scp> identifies patients with chronic myeloid leukaemia with a low probability of achieving treatmentâ€free remission. British Journal of Haematology, 0, , .	1.2	2
39	Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naÃ¯ve Patients. Blood, 2014, 124, 4515-4515.	0.6	1
40	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. Blood, 2014, 124, 647-647.	0.6	1
41	High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment. Blood, 2015, 126, 1419-1419.	0.6	1
42	A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. Blood, 2015, 126, 596-596.	0.6	1
43	In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy. Blood, 2016, 128, 3957-3957.	0.6	1
44	High Plasma Levels of TGF-Î± and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML. Blood, 2014, 124, 1788-1788.	0.6	1
45	Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib. Blood, 2018, 132, 1728-1728.	0.6	1
46	Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 2585-2585.	0.6	1
47	Editorial: Molecular Mechanisms of Multiple Myeloma. Frontiers in Oncology, 2022, 12, 870123.	1.3	1
48	Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. Molecular Genetics and Genomics, 2018, 293, 1217-1229.	1.0	0
49	Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,. Blood, 2011, 118, 3501-3501.	0.6	0
50	Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,. Blood, 2011, 118, 3540-3540.	0.6	0
51	Global DNA Methylation Analysis Identifies Key Pathway Differences Between Poor (Low OCT-1 Activity) and Standard Risk CP-CML Patients At Diagnosis. Blood, 2012, 120, 3730-3730.	0.6	0
52	Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.. Blood, 2012, 120, 2396-2396.	0.6	0
53	Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARÎ³) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Blood, 2013, 122, 1470-1470.	0.6	0
54	Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes. Blood, 2014, 124, 698-698.	0.6	0

#	Article	IF	Citations
55	High Peroxisome Proliferator-Activated Receptor-Gamma (PPARÎ³) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. Blood, 2015, 126, 2770-2770.	0.6	0
56	Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission. Blood, 2021, 138, 2559-2559.	0.6	0
57	Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair. Blood, 2020, 136, 37-38.	0.6	0